Comparison · NCT00623623-e441d5e0
Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. Trial comparisons, record NCT00623623-e441d5e0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00623623-e441d5e0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.122 | 0.103 | 0.145 | wilson | |
| Risk in group 2 | 0.142 | 0.122 | 0.166 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0202 | -0.0507 | 0.0104 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.858 | 0.681 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.839 | 0.643 | 1.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on Tenecteplase (Group A) than on Primary PCI (Group B) | 49.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tenecteplase (Group A) | Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment) | 116 | 949 | OG000 |
| Group 2 | Primary PCI (Group B) | Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.~Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines. | 135 | 948 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
- Description
- The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).
- Time frame
- 30 days
- Population
Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).
Source ClinicalTrials.gov
Trial
- Title
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- NCT number
- NCT00623623
- Phases
- PHASE3
- Conditions
- Myocardial Infarction
- Interventions
- primary PCI, enoxaparin, catheterisation, tenecteplase, clopidogrel
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2019-08-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00623623?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00623623-e441d5e0